分析师指出，计算设备销售的持续强劲，以及市场对任天堂(NTDOY.US)Switch新机型发布的积极反 应，是推动季度销售增长的主要动力。这部分增长足以抵消因房地产市场低迷对电视和家电品类销售造 成的持续拖累。报告还提到，关税带来的价格上涨并未对需求产生显著负面影响，因消费者难以区分关 税相关的价格变化与产品技术升级带来的价格差异，且公司与供应商共同努力减轻了其对需求的冲击。 智通财经APP获悉，百思买(BBY.US)将于8月28日美股盘前公布2025财年第二季度财报。面对日益激烈 的市场竞争，这家消费电子零售商正承受着维持盈利能力的巨大压力。在消费者偏好转变与全行业促销 浪潮的双重挑战下，投资者与分析机构正密切关注其财务表现与战略调整，以评估未来前景。 至于全年与长期指引，摩根大通预计百思买2025年下半年指引有望维持不变，而2027年盈利增长值得期 待。 市场普遍预期，百思买Q2营收为92.31美元，同比下降0.6%，同店销售额下降0.5%，每股收益为1.20 元，同比下降10.2%。 该行认为，考虑到下半年业绩在全年占比更高，且商品关税对消费者需求的影响仍存在不确定性，叠加 上半年整体业绩与预期基本一致 ...

Investment Rating - The report does not explicitly state an investment rating for the company or industry Core Insights - Celestica achieved Q2 2025 revenues of $2.89 billion and adjusted EPS of $1.39, both exceeding the high end of guidance ranges. The adjusted operating margin reached 7.4%, the highest in company history, and adjusted ROIC was 35.5%, up from 26.6% year-over-year, driven by higher operating profit and strong working capital management [1][9]. Summary by Sections Overall Performance - Celestica's Q2 2025 revenue was $2.89 billion, with an adjusted EPS of $1.39, surpassing expectations. The adjusted operating margin was 7.4%, marking a historical high for the company. The adjusted ROIC increased to 35.5% from 26.6% the previous year, attributed to improved operating profit and effective working capital management [1][9]. Segment Performance - **ATS Segment**: Revenue totaled $819 million, a 7% year-over-year increase, driven by strong demand in capital equipment and recovery in industrial businesses. The segment margin improved to 5.3%, up 70 basis points, mainly due to enhanced profitability in the A&D business. ATS accounted for 28% of total revenue [2][10]. - **CCS Segment**: Revenue reached $2.07 billion, up 28% year-over-year, propelled by a 75% growth in the communications end market. HPS networking revenues surged 82% to $1.2 billion, representing 43% of total revenue, due to the ramp-up of 800G switch programs and strong demand from hyperscalers. The segment margin improved to 8.3%, up 130 basis points, benefiting from a higher mix of HPS revenues and productivity gains. CCS comprised 72% of total revenue [2][11]. Balance Sheet and Cash Flow - Inventory balance was $1.92 billion, increasing by $130 million sequentially and $74 million year-over-year. Capital expenditures were $33 million, representing 1.1% of revenue. Free cash flow for the quarter was $120 million, up $54 million year-over-year. Gross debt stood at $823 million, with a net debt position of $509 million and a leverage ratio of 0.9, improving by 0.2 sequentially [3][12]. Revenue and EPS Guidance - For Q3 2025, revenue is projected between $2.875 billion and $3.125 billion, indicating a 20% growth at the midpoint. Adjusted EPS is anticipated to be between $1.37 and $1.53, reflecting a 39% growth at the midpoint. Assuming midpoint results, the non-GAAP operating margin is expected to be 7.4%, up 60 basis points year-over-year, with an adjusted effective tax rate of approximately 19% [4][13]. End Market Outlook - **ATS Segment**: Revenue is expected to decline in the low single-digit percentage range due to reduced A&D volumes from the non-renewal of a margin-dilutive program [5][14]. - **CCS Segment**: Communications end market revenue is projected to grow in the low 60% range, supported by ongoing demand for networking switches. However, enterprise end market revenue is expected to decrease by mid-20% due to a transition in AI/ML compute programs, with new generation programs ramping in Q3 [5][15]. Annual Financial Outlook - Revenue guidance for 2025 has been raised from $10.85 billion to $11.55 billion, representing a year-over-year growth of 20%. Adjusted EPS is increased from $5 to $5.50 per share, reflecting a year-over-year growth of 42%, with an anticipated non-GAAP operating margin of 7.4% [6][16].

Core Viewpoint - QIAGEN reported a strong start to Q1 2025 with net sales of $483 million, a 5% increase year-over-year, driven by efficiency improvements and the discontinuation of the NeuMoDx clinical PCR testing system [2][3][5]. Financial Performance - Net sales for Q1 2025 reached $483 million, up from $459 million in Q1 2024, reflecting a 5% increase. On a constant exchange rate (CER) basis, net sales grew by 7% [6]. - Adjusted operating income rose by 22% to $144 million, with an adjusted operating margin increasing by 4.1 percentage points to 29.8% [7]. - Adjusted diluted EPS for Q1 2025 was $0.55, exceeding the expected minimum of $0.50, while diluted EPS was $0.41, up from $0.36 in Q1 2024 [8]. Sales Breakdown - Diagnostic solutions sales grew by 11% year-over-year, with a 14% increase when excluding the discontinued NeuMoDx system. Key contributors included QuantiFERON and QIAstat-Dx, which saw sales growth of 16% and 37% respectively [9][10]. - PCR/nucleic acid amplification sales increased by 14%, primarily due to the adoption of the QIAcuity digital PCR system [10]. - Sample technologies experienced a slight decline of 1%, attributed to reduced demand for manual kits and cautious capital spending trends [9]. Future Outlook - QIAGEN reaffirmed its 2025 fiscal year net sales growth expectation of approximately 4%, with core sales growth projected at around 5% [5][13]. - The adjusted diluted EPS forecast for 2025 was raised to approximately $2.35, with an operating margin target of over 30% [5][13].

Investment Rating - The report maintains a "Strong Buy" rating for the company with a target price of 67 CNY [1][9]. Core Views - The company reported a steady start to 2025, with Q1 revenue of 4.36 billion CNY, a year-on-year increase of 1.5%, and a net profit attributable to shareholders of 470 million CNY, up 4.6% year-on-year [1][9]. - The company is expected to continue its stable performance, supported by a healthy inventory and practical operational strategies, with a projected dividend yield of approximately 4.6% based on a 100% payout ratio [9]. Financial Performance Summary - In Q1 2025, the company achieved a sales volume of 884,000 kiloliters, a year-on-year increase of 1.93%, with an average price per ton of 4,930 CNY, down 0.46% year-on-year [9]. - The gross profit margin improved to 48.4%, an increase of 0.5 percentage points year-on-year, driven by cost advantages and scale effects [9]. - The company’s operating profit margin for Q1 2025 was 26.3%, with a net profit margin of 21.6% [10]. Future Projections - The company forecasts total revenue of 14.83 billion CNY for 2025, with a year-on-year growth rate of 1.3% [4]. - The net profit attributable to shareholders is projected to reach 1.27 billion CNY in 2025, reflecting a growth rate of 13.9% [4]. - Earnings per share (EPS) are expected to increase from 2.30 CNY in 2024 to 2.62 CNY in 2025 [4]. Market Strategy - The company plans to deepen its core market presence while optimizing its product mix and increasing market share, particularly in non-traditional channels [9]. - New product launches, such as the Chongqing Craft Beer, are aimed at enhancing brand influence and market penetration [9].